Ternary Therapeutics
London biotech founded in 2024 designing molecular glues with AI. In March 2026 it announced a €4.1 million seed.
Europe's most interesting startup stories. Every week.
No spam. Unsubscribe anytime.
Podcast Episode
🎙️ Deep Dive
Daily News – March 16, 2026
Listen to the episodeAbout Ternary Therapeutics
Ternary Therapeutics uses AI, physics-based modelling and experimental validation to design molecular glues, small therapeutic molecules that induce interactions between proteins. The company (Ternary Therapeutics Ltd, incorporated on 8 October 2024) is based in London; the founders are Chris Tame, CEO, and Andrew Potterton, CTO. In March 2026 it announced a €4.1 million (£3.6 million) seed led by daphni, with Pace Ventures, i&i Biotech Fund and the UK Innovation & Science Seed Fund.
The Story
Ternary Therapeutics was founded in London in 2024 by Chris Tame and Andrew Potterton; it came out of stealth in March 2025.
Products & Services
Key Products
- Molecular glue progettate con AI
Core Use Cases
- Designing small therapeutic molecules
- Experimental validation
Market & Clients
Geographic Presence
Funding & Investors
Funding Rounds
- 2026 - Seed: €4,1M (£3,6M)
Lead: daphni
Key Investors
Founding Team
Founders
Similar Startups
Oxford Medical Simulation
UK clinical-simulation company using VR and AI, founded in 2017. On 16 March 2026 it announced £5 million of growth financing from Salica.
Read AnalysisBioniq
London company founded in 2019 offering supplement formulas personalised from a customer assessment. In 2026 Herbalife acquired its core assets.
Read AnalysisSTORM Therapeutics
Biotech company developing targeted therapies using proprietary cell-targeting technology.
Read AnalysisSources
- Ternary Therapeutics — Ternary Therapeutics
- TERNARY THERAPEUTICS LTD - Companies House — Companies House
- Ternary Therapeutics - Team — Ternary Therapeutics
- UKI2S - Ternary Therapeutics — UK Innovation & Science Seed Fund
- Ternary Therapeutics - News — Ternary Therapeutics
- Ternary Therapeutics targets undruggable proteins with AI-designed molecular glues — EU-Startups